Gastric fibrinolysis.

PubWeight™: 0.93‹?›

🔗 View Article (PMID 807)

Published in Thromb Diath Haemorrh on November 15, 1975

Authors

I M Nilsson, S E Bergentz, U Hedner, K Kullenberg

Articles citing this

Clot lysis by gastric juice: an in vitro study. Gut (1989) 1.29

Antifibrinolytic therapy in genitourinary tract surgery. J Clin Pathol Suppl (R Coll Pathol) (1980) 0.75

Fibrinolysis and gastrointestinal haemorrhage. J Clin Pathol Suppl (R Coll Pathol) (1980) 0.75

Histamine and tissue fibrinolytic activity in duodenal ulcer disease. Dig Dis Sci (1998) 0.75

Articles by these authors

Molecular pathology of haemophilia B. EMBO J (1989) 2.74

Solitary aneurysms of the iliac arterial system: an estimate of their frequency of occurrence. J Vasc Surg (1989) 2.69

Renal artery aneurysms. Natural history and prognosis. Ann Surg (1983) 2.21

Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis? Am J Obstet Gynecol (1989) 2.06

Thromboembolic disease--critical evaluation of laboratory investigation. Thromb Haemost (1992) 1.93

Fibrinolytic activity of human veins. Lancet (1967) 1.91

AHF related protein in clinical praxis. Scand J Haematol (1974) 1.78

Defective fibrinolysis in blood and vein walls in recurrent "idiopathic" venous thrombosis. Acta Chir Scand (1972) 1.74

The incidence and distribution of CpG----TpG transitions in the coagulation factor IX gene. A fresh look at CpG mutational hotspots. Nucleic Acids Res (1990) 1.64

Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) (1980) 1.64

Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 1.61

Measurement of basal levels of factor VIIa in hemophilia A and B patients. Blood (1992) 1.61

A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res (1980) 1.59

Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost (2007) 1.56

Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemost (1991) 1.53

Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate. Lancet (1990) 1.53

Intrauterine death and circulating anticoagulant ("antithromboplastin"). Acta Med Scand (1975) 1.51

A nascent secretory protein may traverse the ribosome/endoplasmic reticulum translocase complex as an extended chain. J Biol Chem (1996) 1.51

Determination of plasminogen in clots and thrombi. Thromb Diath Haemorrh (1966) 1.48

Coagulation and fibrinolytic studies during pregnancy. Acta Obstet Gynecol Scand (1967) 1.48

Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol (1975) 1.47

Haemophilia prophylaxis in Sweden. Acta Paediatr Scand (1976) 1.46

The cadaveric kidney in clinical transplantation. Scand J Urol Nephrol (1968) 1.45

Haemophilia prophylaxis in young patients--a long-term follow-up. J Intern Med (1997) 1.44

Intravascular coagulation and acute renal failure in a child with mycoplasma infection. Acta Med Scand (1971) 1.44

Influence of aprotinin, a protease inhibitor, on porcine E. coli shock. Studies on coagulation, fibrinolytic and hemodynamic response. Acta Chir Scand (1989) 1.42

[Threatened future of plasma products. Who is responsible?]. Lakartidningen (1996) 1.39

Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A (1989) 1.35

Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. J Vasc Surg (1993) 1.33

Amino acid sequence and posttranslational modifications of human factor VIIa from plasma and transfected baby hamster kidney cells. Biochemistry (1988) 1.32

The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology (1998) 1.30

Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol (1965) 1.29

Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost (2009) 1.27

Renal blood flow measurement with xenon-133 at the time of operation for renal artery stenosis. Surgery (1966) 1.27

Value of renal blood flow measurement with xenon-133 at the time of kidney transplantation. Ann Surg (1967) 1.25

Two genetic variants of von Willebrand's disease. N Engl J Med (1973) 1.25

Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood (1998) 1.23

Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC). J Clin Invest (1982) 1.23

[Risk of thromboembolism with oral contraceptives]. Lakartidningen (1967) 1.23

Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology (1997) 1.21

Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J (Clin Res Ed) (1985) 1.19

Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease. N Engl J Med (1983) 1.18

The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood (1997) 1.15

Coagulation and fibrinolytic studies during use of gestagens. Acta Obstet Gynecol Scand (1967) 1.14

Catheter material and blood coagulation studies in vitro. Scand J Haematol (1969) 1.13

Fibrinolysis in newborns. Acta Paediatr Scand (1970) 1.12

High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol (2001) 1.12

Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest (1983) 1.12

New aspects of the pathogenesis of thrombo-embolism. Prog Surg (1973) 1.11

Hematocrit, plasma protein, plasma volume, and viscosity in early hypertensive disease. Am Heart J (1966) 1.11

Clinical experience with determination of fibrinogen degradation products. Acta Med Scand (1971) 1.10

Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy. Lancet (1988) 1.09

Fibrin degradation products and ovarian tumours. Br Med J (1971) 1.08

Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chir Scand (1970) 1.08

Fifty uremic patients treated with renal homotransplantation. Scand J Urol Nephrol (1968) 1.08

A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies. Blood (1981) 1.07

Thrombosis and oral contraceptives: possible predisposition. Br Med J (1973) 1.07

Coagulation and fibrinolytic studies during continuous use of low dose gestagen. Acta Endocrinol (Copenh) (1970) 1.07

Immunosuppressive treatment in haemophiliacs with inhibitors to factor VIII and factor IX. Scand J Haematol (1976) 1.06

Shelf-life of bank blood and stored plasma with special reference to coagulation factors. Transfusion (1983) 1.06

"Fibrinolytic capacity" in healthy volunteers as estimated from effect of venous occlusion of arms. Acta Chir Scand (1972) 1.05

Acute renal impairment due to a primary aortocaval fistula is normalised after a successful operation. Eur J Vasc Endovasc Surg (1999) 1.05

Binding of delta-1-tetrahydrocannabinol to human plasma proteins. Biochem Pharmacol (1970) 1.05

Value of streptokinase and heparin in treatment of acute deep venous thrombosis. A coded investigation. Acta Chir Scand (1968) 1.04

Genetic variants of von Willebrand's disease. Br Med J (1972) 1.03

Our experience in Sweden with prophylaxis on haemophilia. Bibl Haematol (1970) 1.03

Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood (1983) 1.02

Fibrinolysis and subarachnoid haemorrhage. Inhibitory effect of tranexamic acid. A clinical study. Acta Neurol Scand (1972) 1.02

Blood flow in kidney transplants. A clinical evaluation of the 133 xenon method. Scand J Urol Nephrol (1968) 1.02

Thrombosis in the superior mesenteric and portal veins: report of a case treated with thrombectomy. Surgery (1974) 1.02

Coagulation and fibrinolysis in chronic panniculitis. Acta Derm Venereol (1970) 1.02

Factor XIII (fibrin stabilising factor) in Henoch-Schönlein's purpura. Acta Paediatr Scand (1977) 1.02

Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia (2009) 1.02

An HphI-polymorphism in exon 28 of the von Willebrand factor gene, and its frequency among patients with various forms of von Willebrand's disease. Br J Haematol (1991) 1.02

Factor VIII antigen in the vessel walls in von Willebrand's disease and haemophilia A. Scand J Haematol (1974) 1.02

Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma (2001) 1.02

The role of beta-1-adrenoceptors in the renin release response to graded renal sympathetic nerve stimulation. Pflugers Arch (1980) 1.01

Pregnancy and parturition in a patient with severe Glanzmann's thrombasthenia. Scand J Haematol (1981) 1.01

Serum fibrin-fibrinogen degradation products in acute myocardial infarction. Lancet (1972) 1.00

Diagnostic symptoms of severe and moderate haemophilia A and B. A survey of 140 cases. Acta Paediatr Scand (1990) 1.00

"Fibrinolytic capacity" in healthy volunteers at different ages as studied by standardized venous occlusion of arms and legs. Acta Med Scand (1972) 0.99

Effect of treatment with combined phenformin and ethyloestrenol on the coagulation and fibrinolytic systems. Scand J Haematol (1970) 0.99

Fibrinolytic activity of human veins in arms and legs. Thromb Diath Haemorrh (1968) 0.99

Autologous blood transfusion in revision hip arthroplasty. A prospective, controlled study of 30 patients. Acta Orthop Scand (1992) 0.98

Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity. Br J Haematol (1991) 0.98

Surgical treatment of renal artery stenosis with impending uremia. Clin Nephrol (1975) 0.98

Deep venous thrombosis of the arm: a study of coagulation and fibrinolysis. Br Med J (Clin Res Ed) (1981) 0.98

Two factor IX mutations in the family of an isolated haemophilia B patient: direct carrier diagnosis by amplification mismatch detection (AMD). Hum Genet (1990) 0.98